Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

27.8%

5 terminated/withdrawn out of 18 trials

Success Rate

64.3%

-22.2% vs industry average

Late-Stage Pipeline

11%

2 trials in Phase 3/4

Results Transparency

67%

6 of 9 completed trials have results

Key Signals

3 recruiting6 with results

Enrollment Performance

Analytics

Phase 2
8(47.1%)
Phase 1
7(41.2%)
Phase 3
2(11.8%)
17Total
Phase 2(8)
Phase 1(7)
Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (18)

Showing 18 of 18 trials
NCT07525427Phase 2Recruiting

Bactericidal Activity of TBD09 in Combination With Other Drugs in Pulmonary Tuberculosis

Role: lead

NCT06062238Phase 3Active Not Recruiting

Study to Assess Efficacy and Safety of M72/AS01E-4 Mycobacterium Tuberculosis (Mtb) Vaccine in Adolescents and Adults

Role: lead

NCT07517445Phase 2Recruiting

Bactericidal Activity and Safety of Nicotinamide in Combination With Bedaquiline, Pretomanid, and Linezolid in Drug-susceptible Pulmonary Tuberculosis

Role: lead

NCT06707142Phase 1Completed

A Trial in Healthy Adult Participants to Evaluate the Safety, Tolerability, and Behavior in the Body of TBD11

Role: lead

NCT07094932Phase 1Completed

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBD09

Role: lead

NCT06408857Phase 1Recruiting

Study To Evaluate Safety, Tolerability, and Pharmacokinetics of MAM01 in African Population

Role: lead

NCT04556981Phase 2Completed

Safety and Immunogenicity of a Mycobacterium Tuberculosis Vaccine M72/AS01E in Participants With Well-controlled HIV

Role: lead

NCT04152161Phase 2Terminated

Bacille Calmette Guerin (BCG) Revaccination of Healthy Adolescents for the Prevention of Mycobacterium Tuberculosis Sustained Infection

Role: lead

NCT05952076Phase 3Terminated

Impact of Bi-26 Supplementation on Weight Gain in Underweight Infants

Role: lead

NCT05971602Phase 2Terminated

Efficacy and Safety Evaluation of Two to Four Months of Treatment With the Combination Regimens of DBOS and PBOS in Adults With Pulmonary Tuberculosis

Role: lead

NCT05891236Phase 1Completed

Safety, Tolerability, Pharmacokinetics and Protective Efficacy of MAM01 in Healthy Adults

Role: lead

NCT05190146Completed

Epidemiologic Study to Assess the IGRA Positivity in Populations With a High TB Burden

Role: lead

NCT05824091Phase 1Completed

Safety, Tolerability, Pharmacokinetics (PK), and Food Effect of MK-7762 in Healthy Adults

Role: lead

NCT05118386Phase 1Completed

Safety, Tolerability, and Pharmacokinetics of RSV Monoclonal Antibody RSM01 in Healthy Adults

Role: lead

NCT04602975Phase 2Completed

A Study to Investigate the Safety and Immunogenicity of the SF2a-TT15 Synthetic Carbohydrate-based Conjugate Vaccine Against Shigella Flexneri 2a

Role: collaborator

NCT04176250Phase 2Completed

Early Bactericidal Activity of TBA-7371 in Pulmonary Tuberculosis

Role: lead

NCT05035680Phase 1Withdrawn

Proof of Concept Trial of Adjuvant Activity of SWE, a Squalene-based -Oil-in-water Emulsion

Role: lead

NCT04504032Phase 2Terminated

A Trial to Evaluate Safety and Efficacy of Rivaroxaban (COVID-19)

Role: lead

All 18 trials loaded